Recherche et médicaments : révolutions scientifiques et évolutions multiformes des entreprises

Abstract

A new scientific era is opening in drug research. Greater complexity, the exploding costs of developing new products and the necessity of a multidisciplinary approach all have implications for the structure of companies and the organization of research. Despite quite real advantage, France, we must admit, does not have a "pole of excellence" capable of positioning itself internationally and helping the drug industry benefit from a host of new companies innovating in ground-breaking techniques.